SIRT2调控脓毒性休克患者离体PBMC黏附
研究纳入脓毒性休克患者与对照,刺激全血和PBMC±LPS,检测血浆细胞因子、PBMC黏附、CD18活化、SIRT2表达及细胞因子反应。发现脓毒性休克患者血浆TNF和IL-1β对LPS反应减弱(内毒素耐受),内毒素耐受的PBMC高表达SIRT2且黏附、CD18活化和跨膜迁移减弱(黏附耐受)。SIRT2抑制剂AK-7通过CD18活化逆转内毒素和黏附耐受,改善跨膜迁移缺陷,并提高脓毒性休克患者单核细胞来源巨噬细胞的吞噬功能。作者认为PBMC黏附可作为低炎症的生理生物标志物,SIRT2抑制是治疗脓毒症相关低炎症的潜在策略。
要点
- 脓毒性休克患者血浆TNF和IL-1β对LPS反应减弱,表现为内毒素耐受。
- 内毒素耐受的脓毒性休克患者PBMC高表达SIRT2,且黏附、CD18活化和跨膜迁移均减弱(黏附耐受)。
- SIRT2抑制剂AK-7可逆转脓毒性休克患者PBMC的内毒素耐受和黏附耐受,并恢复跨膜迁移。
- AK-7可改善脓毒性休克患者单核细胞来源巨噬细胞的吞噬功能。
- 作者认为PBMC黏附可作为检测低炎症的生理生物标志物,SIRT2抑制是潜在治疗策略。
适用人群与场景
- 脓毒性休克患者与健康对照的外周血单个核细胞(PBMC)和全血,以及单核细胞来源巨噬细胞。
处置流程与药物剂量
- SIRT2抑制剂AK-7用于离体内毒素耐受的PBMC和THP-1细胞,分析细胞黏附、CD18活化和跨膜迁移±LPS。
- AK-7用于脓毒性休克患者单核细胞来源巨噬细胞,分析吞噬功能。
研究设计与关键结果
- 脓毒性休克患者血浆TNF和IL-1β对LPS反应减弱,表现为内毒素耐受。
- 内毒素耐受的脓毒性休克患者PBMC高表达SIRT2,且黏附、CD18活化和跨膜迁移减弱(黏附耐受)。
- SIRT2抑制剂AK-7通过CD18活化逆转脓毒性休克患者PBMC的内毒素耐受和黏附耐受,并逆转内毒素耐受PBMC的跨膜迁移缺陷。
- AK-7改善脓毒性休克患者单核细胞来源巨噬细胞的吞噬功能。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PBMC黏附可作为检测低炎症的生理生物标志物。
- 作者认为SIRT2抑制是治疗脓毒症相关低炎症的潜在策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Septic shock (SS) is deadly. Sepsis-immune response transitions from an endotoxin-sensitive, hyper-inflammatory phase to an endotoxin-tolerant hypo-inflammatory phase. In mice, we implicated sirtuin 2 (SIRT2) for prolonged hypo-inflammation using leukocyte adhesion, the earliest in vivo inflammatory response to cytokine, chemokine, and metabolite stimuli. The role of SIRT2 in human sepsis remains unknown. We hypothesized that (1) peripheral blood mononuclear cells (PBMCs) adhesion response can be used as a physiological biomarker of hypo-inflammation, and (2) SIRT2 regulates the functions of PBMCs and macrophages during the hypo-inflammatory phase of human sepsis.
METHODS: We stimulated control and SS whole blood and PBMCs ± lipopolysaccharide (LPS) and investigated plasma cytokines, PBMC cell adhesion to intercellular adhesion molecule-1-coated plates, adhesion molecule CD18 activation, SIRT2 expression, and cytokine response. In adhesion-/endotoxin-tolerant PBMCs and THP-1 cells treated ± SIRT2 inhibitor AK-7, we analyzed cell adhesion, CD18 activation, and transmigration ± LPS. In monocyte-derived macrophages from SS versus controls ± AK-7, we analyzed phagocytosis.
RESULTS: We found the following: (1) Muted plasma tumor necrosis factor and interleukin-1β-response to LPS in SS versus control (endotoxin tolerance); (2) endotoxin-tolerant SS-PBMCs exhibit high SIRT2 expression, and muted adhesion (adhesion tolerance), CD18 activation, and transmigration with LPS; and (3) SIRT2 inhibitor AK-7 reverses endotoxin and adhesion tolerance in SS-PBMCs via CD18 activation, reverses the defective transmigration of endotoxin-tolerant PBMCs, and improves phagocytosis in monocyte-derived macrophages from SS patients.
CONCLUSIONS: PBMC adhesion, a physiological biomarker, can be used to detect hypoinflammation. Defective PBMC and macrophage function in SS patients occur via high SIRT2 expression. SIRT2 inhibition is a potential therapeutic strategy for treating sepsis-associated hypo-inflammation.
参考来源
- Shrestha D, Pant B, Ahuja A, et al. SIRT2 Regulates EX VIVO PBMC Adhesion in Septic Shock Patients. Shock. 2025. PMID: 41460289. doi:10.1097/SHK.0000000000002773
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。